# Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy

> **NCT00149942** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 23 (actual)

## Conditions studied

- Kidney Transplantation
- Liver Transplantation

## Interventions

- **DRUG:** Enteric-coated Mycophenolate sodium (EC-MPS)

## Key facts

- **NCT ID:** NCT00149942
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00149942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00149942, "Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00149942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*